5 Biotech Stocks To Boost Your Portfolio

Sun, 04/22/2012 - 08:18 EDT - Seeking Alpha

By Ry Frank:I believe there are many reasons why Human Genome Sciences (HGSI) is currently undervalued in the biotech sector. A skeptic could argue that the firm's stock price has been in a tailspin as of recently, but I consider that to be extremely shortsighted. For starters, the price of this stock has been hovering right around $7, consistently, and minor fluctuations are to be expected every now and then. Next, and more importantly, HGSI is taking an unorthodox approach with its new drug, Benlysta.Benlysta is unique to the company for two major reasons. First, Benlysta is on the market already. This is immensely significant because Benlysta is the first drug approved by the FDA to treat Lupus since 1955. Since there are no current competitors, or past competitors for this drug, I do not see why Human Genome Sciences won't be able to take advantage of this near monopolistic situation.Complete Story »

Original article
Login or register to post comments

Lupus drug Benlysta an expected blockbuster
The FDA is expected to make an approval decision this week on a drug that would mean worlds to both the lupus-suffering patient population and to the drug’s developer,
FDA Approves Human Genome (HGSI), Glaxo Drug Benlysta
The first new drug to treat Lupus in over 50 years won U.S. approval on Wednesday. Human Genome Sciences, Inc. (HGSI) and GlaxoSmithKline PLC (GSK) said that the U.S. Food and Drug Administration [FDA] has approved ‘Benlysta’, an injectable drug designed to relieve flare-ups and pain caused by the disabling disease.
Human Genome Spikes On Sales: Good Time To Consider Buying
By VFC: Even on a day when the DOW drops 300 points at the open, there's sure to be a good news story somewhere.
Human Genome Sciences Evenly Poised After FDA Approval
Zacks.com submits: We are maintaining our Neutral recommendation on Human Genome Sciences Inc. (HGSI) with a target price of $29.00.
Will Human Genome's Lupus Drug Pass Muster?
Pharmalot submits: On Tuesday, an FDA advisory panel will review the first new treatment for lupus in decades. And the early indications are that Benlysta, which is being developed by Human Genome Sciences (HGSI), will win an endorsement. At least that’s how some Wall Street analysts are interpreting the FDA briefing documents filed Friday morning, even though the stock is trading down.
Thursday Options Update: HGSI, BSX, DFS, CSCO, LVLT, AMGN & IBB
Andrew Wilkinson submits: Human Genome Sciences, Inc. (HGSI) – Shares in Human Genome Sciences are up 8.9% to trade around $26.49 in the final hour of the trading session on speculation the firm could become an attractive takeover target if its lupus drug treatment, Benlysta, wins approval next month.
Eye on Human Genome Sciences as It Fulfills Its Promise
Todd Johnson submits:Human Genome Sciences (HGSI) is finally coming to market with the full FDA approved medication. The company's early years hype, and later years near-death stock experience, can all be viewed in perspective.
Brightening Prospects for Biotech Stocks
Thomas Kee submits: Attention editors: Please include the stock reports in this article as they help investors manage risk in these stocks.
Is This the Week for Human Genome's Benlysta?
VFC submits: It's been over fifty years since the US Food and Drug Administration [FDA] has approved a new drug to treat the mysterious illness lupus, which turns a victim's body against itself, but all that can change this week as an approval decision is expected by Thursday for Human Genome Sciences lupus drug, Benlysta.This decision was originally expected to come in December, although the FDA announced a three-month delay at that time, bringing us to this week's decision.A
Friday Options Update: HGSI, MDRX, JPM, ESV, FLR, SD
Andrew Wilkinson submits: Human Genome Sciences, Inc. (HGSI) – Shares in biotechnology company Human Genome Sciences are down 3.95% this afternoon at $25.23 as of 3:15 pm, but one options trader populating the December contract today is positioning for the stock to rebound ahead of a key FDA decision on its lupus drug treatment, Benlysta.

Main menu

Secondary menu

5 Biotech Stocks To Boost Your Portfolio

Related

Latest

User login

Our Blog

Markets Map

Follow Us

Secondary menu